- Conditions
- High-risk Large B-cell Lymphoma (LBCL)
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease
- Interventions
- Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
- Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colitis, Ulcerative, Crohn Disease
- Interventions
- Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Cypress, California • Miami, Florida
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more
- Conditions
- ALL
- Interventions
- Music Therapy, Massage Therapy
- Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, dexamethasone, lenalidomide
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia, Relapsed Cancer, Refractory Leukemia
- Interventions
- Roginolisib, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Jennifer R. Brown, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Parkinson's Disease
- Interventions
- Aerobic walking, Usual care with PD specific health education
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Interventions
- BPX-601, Rimiducid
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 13
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- PD-1inhibitor - LVGN 3616, CD 40 Agonist - LVGN 7409
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia
- Interventions
- CD 40
- Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Spinal Cord Injuries
- Interventions
- CPH + hand training, CD-LD + hand training, ATX + hand training, Placebo + hand training
- Drug
- Lead sponsor
- Bronx VA Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
- Interventions
- Life completion and preparation, Attention Control
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Daratumumab, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more
- Conditions
- Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Renal Disease
- Interventions
- Outlook Attention Control, Outlook Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Anxiety in Pregnancy, Mood Disorder Due to Specified Medical Condition
- Interventions
- BE-OR: Brief Intervention to the Operating Room, Interaction: Facetime with Clinical Provider
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Crohn's Disease
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Celiac Disease
- Interventions
- GROW+ Project
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Interventions
- APX005M, Cabiralizumab, Nivolumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 12
- States / cities
- Duarte, California • Stanford, California • Tampa, Florida + 8 more
- Conditions
- IBD
- Interventions
- Capsule endoscopy
- Device
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
- Interventions
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Procedure · Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland